While great strides have been made the fight against cancer with new therapies, dose-limiting toxicities of these agents can have a big impact on the quality of life for patients and lead doctors to alter dosing at the price of optimal outcomes. Rather than treating the symptoms of the side effects of cancer drugs, OnQuality Pharmaceuticals is developing a pipeline of therapies that target the biologic pathways that at their source. It is developing targeted supportive therapies to treat such things as dermatologic conditions and diarrhea caused by cancer medicines. We spoke to Michael McCullar, CEO of OnQuality, about the need his company is addressing, its pipeline, and how he expects others to think about the value of the therapies the company is developing.
top of page
bottom of page